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Abstract
Background: The cause of immune-mediated myositis (IMM), characterized by recurrent, rapid-onset muscle
atrophy in Quarter Horses (QH), is unknown. The histopathologic hallmark of IMM is lymphocytic infiltration of
myofibers. The purpose of this study was to identify putative functional variants associated with equine IMM.
Methods: A genome-wide association (GWA) study was performed on 36 IMM QHs and 54 breed matched
unaffected QHs from the same environment using the Equine SNP50 and SNP70 genotyping arrays.
Results: A mixed model analysis identified nine SNPs within a ~ 2.87 Mb region on chr11 that were significantly
(Punadjusted < 1.4 × 10
− 6) associated with the IMM phenotype. Associated haplotypes within this region encompassed
38 annotated genes, including four myosin genes (MYH1, MYH2, MYH3, and MYH13). Whole genome sequencing of
four IMM and four unaffected QHs identified a single segregating nonsynonymous E321G mutation in MYH1
encoding myosin heavy chain 2X. Genotyping of additional 35 IMM and 22 unaffected QHs confirmed an
association (P = 2.9 × 10− 5), and the putative mutation was absent in 175 horses from 21 non-QH breeds.
Lymphocytic infiltrates occurred in type 2X myofibers and the proportion of 2X fibers was decreased in the
presence of inflammation. Protein modeling and contact/stability analysis identified 14 residues affected by the
mutation which significantly decreased stability.
Conclusions: We conclude that a mutation in MYH1 is highly associated with susceptibility to the IMM phenotype
in QH-related breeds. This is the first report of a mutation in MYH1 and the first link between a skeletal muscle
myosin mutation and autoimmune disease.
Keywords: Equine, Genome-wide association, Immunology, Myopathy, Myosin heavy chain 1
Background
Inflammatory myopathies are infectious or immune-
mediated disorders that are characterized by the presence
of lymphocytes in the skeletal muscle. Immune-mediated
myositides (IMMs) are an important cause of morbidity
and, in some cases, mortality in several species including
humans [1], dogs [2], and horses [3, 4]. Common clinical
features include malaise, muscle atrophy, and weakness
with a histopathologic hallmark of inflammatory infil-
trates, particularly lymphocytes, surrounding blood
vessels, and within myocytes [5, 6]. There are several
different IMM subtypes including inclusion body myositis
in humans [7], polymyositis and dermatomyositis in dogs
and humans [5], canine masticatory myositis [8], and
equine IMM [3, 4]. Equine IMM is characterized by CD4
+, CD8+, and CD20+ lymphocytic infiltrates surrounding
blood vessels and infiltrating myofibers without evidence
of rimmed vacuoles [3, 6]. Similar to human IMM, equine
IMM has a bimodal age distribution affecting young
horses (< 8 years of age) or older horses (> 17 years of age)
[3, 9].
Causes of autoimmune diseases such as IMM are not
well understood, but environmental stimuli, combined
with a genetic predilection, appear to be important
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initiating factors [10, 11].The precise environmental trig-
ger for equine IMM is not clear, but 39% of horses with
IMM are reported to have a recent history of infection,
particularly with Streptococci spp., or vaccination with
influenza, herpes virus-1, or Streptococcus equi subsp.
equi 3 to 4 weeks prior to onset [3, 4]. While recurrence
of muscle wasting is reported with equine IMM, an
improvement in clinical signs is often noted following
treatment with corticosteroids. Full muscle mass is
typically regained in 1–10 weeks, with corticosteroid
treatment decreasing the time to full recovery [3].
Genetic associations with IMM have been found with
various major histocompatibility complex loci in humans
and dogs [10, 12]. Because the majority of horses
affected by IMM are of Quarter Horse (QH)-related
breeds and since certain stallions appear to be overrep-
resented in the genetic lineage of QHs with IMM, we
hypothesized that there is an underlying genetic variant
that causes susceptibility to IMM in QHs [3, 13]. The
first objective of this study was to identify associated
genomic regions underlying risk for developing equine
IMM by performing a genome-wide association (GWA)
study of QHs and related breeds with and without IMM
that were housed in the same environment and therefore
exposed to the same risk factors that may result in the
IMM phenotype. The second objective was to evaluate
the region of association from the GWA using whole
genome sequencing to identify a putative functional
variant associated with the equine IMM phenotype. The
third objective was to determine if the alteration
encoded by the putative functional variant altered pro-
tein structure and was targeted by inflammation.
Methods
All blood and muscle samples were collected with approval
from the Animal Care and Use Committee at the University
of Minnesota and University of California, Davis.
IMM case and control selection
GWA cohort
IMM-affected QHs (n = 36; 11 geldings, 10 stallions, and
15 mares) were selected based on a history of muscle
atrophy (particularly of the epaxial or gluteal muscles,
Fig. 1) and the presence of lymphocytes invading myofi-
bers or cuffing blood vessels in a formalin-fixed or fresh
muscle biopsy as previously described [3]. Horses with
type 1 polysaccharide storage myopathy based on
amylase-resistant polysaccharide in myofibers or the
presence of the H309A GYS1 mutation [14] were
excluded. The mean ± SEM age at the time of biopsy
was 4.6 ± 0.8 years (range 0.1–19 years) for IMM-
affected QHs. Due to the importance of environmental
triggers, unaffected QHs (n = 54; 5.6 ± 0.6 years range
1–17; 17 geldings, 3 stallions and 34 mares) were
selected from two herds that had active IMM cases.
Unaffected horses had no history of muscle atrophy or
stiffness consistent with IMM. Horses were selected
such that they were not related at least within one gen-
eration. Of the horses used for the GWA, 1/36 affected
and 41/54 unaffected horses were used in a previous
genetic study [15].
Whole-genome sequencing
From the GWA cohort, four of the most severely
affected IMM QHs (1 gelding, 1 stallion, and 2 mares)
and four unaffected QHs (2 geldings and 2 mares) were
selected for whole-genome sequencing.
Follow-up cohort
The follow-up cohort included an additional 35 IMM
QHs (13 geldings, 11 stallions, 11 mares; mean age at
biopsy 3.4 ± 0.8 years [range 0.5–18 years]), phenotyped
clinically by muscle atrophy (Fig. 1) (n = 25/35) and stiff-
ness (n = 4/35) with mild lymphocytic infiltrates in myo-
cytes or vascular cuffing in muscle samples. Unaffected
QHs (n = 22; 5 geldings, 2 stallions, 15 mares, > 2 years)
in this follow-up cohort were housed on the same prop-
erty as IMM-affected cases and therefore exposed to the
Fig. 1 a Normal muscle mass in an MYH1 E321G homozygote prior to
developing IMM. b The same horse 4 months after an episode of IMM.
The spine is prominent due to loss of epaxial muscles (arrow). c
Atrophy of middle and superficial gluteal muscles (arrow) is present
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same environmental risk factors to develop IMM. While
these horses may have gone on to develop myositis later
in life, all had no history of disease at the time of sam-
pling. All horses in this cohort were genotyped for the
non-synonymous MYH1 E321G variant.
Random QH cohort
A cohort of 28 healthy QHs (n = 22) and a related breed,
Paint horses (6), that were embryo transfer recipient
horses of unknown bloodlines were genotyped for the
putative variant to assess the prevalence of the MYH1
E321G variant in distantly related or unrelated cohorts.
There was no history of IMM in this herd.
Across breed cohort
Genotyping of the MYH1 E321G variant was performed
in a total of 64 horses across 6 breeds (Additional file 1:
Table S1). Additionally, publically mapped whole-
genome sequences from the Sequence Read Archive
(SRA; https:/www.ncbi.nlm.nih.gov/sra) were available
for 110 horses across 21 breeds.
Pedigree analysis
From the original GWA cohort, pedigrees were available
for 23/36 QH. Pedigrees were analyzed using Pedigraph
[16]. Following genotyping of all horses for the MYH1
E321G variant, additional pedigrees were created of indi-
vidual families.
Genome-wide association (GWA)
DNA isolations were prepared from whole blood (Archi-
vePure™ DNA Blood Kit VWR International, Radnor, PA)
or muscle (ArchivePure™ DNA Tissue Kit VWR Inter-
national, Radnor, PA) samples according to the provided
protocols. Genotyping of a subset of samples was per-
formed on the Equine SNP 50K BeadChip (Illumina, San
Diego, CA) (1 IMM and 41 unaffected horses), prior to
the creation of the Equine SNP 70K BeadChip (Illumina,
San Diego, CA). Thirty-five IMM QHs and 13 unaffected
QHs were genotyped across 74,500 SNP markers with the
Equine SNP 70K BeadChip (Illumina, San Diego, CA).
Statistical methods and data analysis
Datasets were merged and only SNPs that passed quality
control settings (minor allele frequency > 1%, genotyping
across individuals > 90%, and Hardy-Weinberg p > 0.001)
were selected. A genome-wide efficient mixed model
association was performed using GEMMA software
using the standardized relatedness matrix option (−gk 2)
[17]. Population stratification was estimated by assessing
the genomic control inflation factor (λ). A Bonferroni
correction for 39,589 tests (the number of useable SNPs)
from the GEMMA analysis, based on a Pgenome-wide of
0.05, was determined as 1.26 × 10− 6.
Haplotype analysis
For chr11, which demonstrated the only genome-wide
significant associations on the GWA, haplotypes were
reconstructed on the individual chromosome using
Haploview [18]. SNPs were filtered based on genotyping
(> 90%) and minor allele frequency (> 1%). Association
testing of both the single markers and haplotypes was
performed using 1000 permutations. The adjusted
haplotype-wide significance threshold was Ppermuted = 0.05.
Whole-genome sequencing
Using Illumina’s TruSeq DNA PCR-free library prepar-
ation kit (Illumina, San Diego, CA, USA) and following
the manufacturer’s instructions, libraries were prepared
with median insert size of 300–400 bp from the four
IMM QHs and four unaffected QHs. The eight libraries
were barcoded and pooled across eight lanes of a 125PE
flow cell on an Illumina HiSeq2500, generating an aver-
age of 10.2× coverage per horse. Following quality trim-
ming, reads were mapped to the EquCab2.0 reference
genome using the Burrows-Wheeler Aligner (BWA)
version 0.7.5a [19] using default settings. After sorting
the mapped reads by the coordinates of the sequence,
PCR duplicates were labeled with Picard tools (http://
sourceforge.net/projects/picard/). The Genome Analysis
Tool Kit (GATK version v.2.7.4) was used to perform
local realignment [20]. Variant calls were made across all
eight samples simultaneously using standard hard filter-
ing parameters or variant quality score recalibration with
Haplotype Caller according to GATK Best Practices
Recommendations [21, 22].
Statistical methods and data analysis
SnpEFF [23] and SnpSift [24] were used to predict the
functional effects of detected variants across the genome
and within chr11 candidate region and filter by segrega-
tion using Fisher’s exact test. Variants were filtered by
region in the entire associated haplotype block on
chr11:49,915,548–56,207,873. To further refine the seg-
regation, an unaffected Arabian horse from a previously
published study [25] was included. Within this region,
segregating variants were further filtered by the Fisher’s
exact allelic P value (< 0.0003), allowing for one hetero-
zygote in the IMM-affected group. Segregating variants
within this region were further evaluated using all publi-
cally available mapped whole-genome sequences in the
NCBI Sequence Read Archive (https://www.ncbi.nlm.-
nih.gov/sra). Putative segregating variants were excluded
if found in > 1 breed other than the QH. In addition to
variant calling, visual inspection of the raw reads using
the Integrated Genomics Viewer [26] within the chr11
region of association was performed. As conservation
scores are not available in the EquCab2.0 genome
browser within UCSC (https://genome.ucsc.edu/), scores
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were determined for each orthologous human variant
using the 100 vertebrate score by phastCons (https://
genome.ucsc.edu/). Whole genome sequences were
deposited in the NCBI Sequence Read Archive (https://
submit.ncbi.nlm.nih.gov/subs/sra/) (SRP119975).
Genotyping
Primer pairs were designed using Primer3Plus software
[27] (F-CCCAAGATCTCAATGGCACT and R-ACCTT
GTGGGAACATTCAGC) to amplify and subsequently
genotype the nonsynonymous MYH1 E321G variant in
an additional cohort of IMM-affected and unaffected
QHs and a cohort of unaffected Arabian horses. Amplifi-
cation of products was performed using endpoint PCR
and visualized with the QIAxcel Advance System (QIA-
GEN, Valencia, CA, USA) and the QIAxcel DNA
Screening Kit (QIAGEN, Valencia, CA, USA). The 20-μL
PCR reactions were comprised of 2 U of Hot-start TAQ
and 2.0 μL of 10× Buffer (Applied Biosystems, Foster
City, CA, USA), 0.25 mM dNTPs (Thermo Fisher,
Waltham, MA, USA), 0.5 μM of both forward and
reverse primers (Invitrogen Life Technologies, Carlsbad,
CA, USA), and 20 ng genomic DNA. Standard PCR con-
ditions were performed as follows: hot-start TAQ activa-
tion and initial denaturation at 95 °C for 10 min;
35 cycles of 95 °C denaturation for 30 s, 60 °C annealing
for 1 min, and 72 °C extension for 1 min; and final
extension at 72 °C for 10 min. PCR products were puri-
fied using ExoSAP-IT® PCR Product Cleanup Kit
(Affymetrix, San Diego, CA, USA). Sanger sequencing
was performed using ABI 2500 automated sequencers.
Resulting sequences were aligned to EquCab2.0 (http://
www.ncbi.nlm.nih.gov/genome/145) and analyzed with
Sequencher® software (Gene Codes Corporation, Ann
Arbor, MI, USA).
Quantitative real-time PCR
Skeletal muscle MYH1 expression was assessed in 14
IMM-affected QH (11 E321G MYH1 homozygotes, 3
heterozygotes) and 11 unaffected horses across various
breeds (all homozygous wild-type). Primers were
designed for MYH1 (F-CACCACCAACCCGTATGACT
and R-GAAGCCCAAGATCTCAATGG) and the refer-
ence gene ACTB (F-AAGGAGAAGCTCTGCTATGT
CG and R-GGGCAGCTCGTAGCTCTTC), RT-qPCR
was performed, and data were analyzed as previously
reported [28].
Protein modeling and side chain analysis
Conformational changes caused by the identified E321G
MYH1 variant were modeled using online G23D tool
[29] and Homo sapiens myosin gene chain A (PDB ID:
4pa0). The amino acid in the mutated position was mod-
eled using SCcomp [30]. Contact surface areas and
solvent accessible surface areas were calculated using
G23D, which applies Voronoi tessellation to allocate
contact surfaces between neighboring atoms [31, 32].
Stability analysis of the E317G variant was performed
using I-Mutant-2 [33], directly accessed from G23D.
Inflammation and muscle fiber type composition
Formalin-fixed or fresh skeletal muscle biopsy specimens
were obtained by referring veterinarians and shipped on
gel packs to the Neuromuscular Diagnostic Laboratory.
Fresh samples were frozen in isopentane suspended in
liquid nitrogen within 48 of the initial biopsy, and
samples were stored at − 80 °C.
In a study of IMM published previously, inflammatory
cell types were identified in fresh muscle samples
obtained from horses of Quarter Horse-related breeds
that presented with a history of gross atrophy of gluteal
and epaxial muscles evident on physical examination
[13]. Macrophages were identified with acid phosphatase
stains, and immunohistochemical staining was used to
identify CD4+, CD8+, and CD20+ [6]. Detailed methods
can be found elsewhere [3, 6]. For the purposes of the
present study, the type of inflammatory cells infiltrating
myofibers was re-assessed in relationship to MYH1
genotype (13 horses GG, 3 horses G/A).
Adequate well-preserved frozen muscle tissue
remained after examining inflammatory cell types from
10 IMM horses that were then used to evaluate fiber
types. In six IMM cases, inflammation was identified in
a formalin-fixed gluteal sample and fiber typing was
performed in a concomitantly submitted fresh semi-
membranosus sample lacking substantial inflammation.
Semimembranosus or gluteal muscle samples from five
horses that were homozygous wild-type for the MYH1
E321G variant were used as unaffected controls.
Unaffected horses had normal muscle mass as assessed
by physical examination and lacked lymphocytes or macro-
phages in muscle biopsies. Frozen samples from semimem-
branosus (4 E321G MYH1 homozygotes, 3 heterozygous, 4
wild-type) and middle gluteal (3 E321G MYH1 homozy-
gotes, 0 heterozygous, 1 wild-type) muscles were assessed.
Serial 10-μm sections stained with hematoxylin and
eosin (HE) and labeled by immunofluorescence for fiber
type were used to identify inflammatory infiltrates within
fiber types. Type 1, 2A, 2AX, and 2X muscle fiber types
were identified by multiple fluorescent labeling accord-
ing to Tulloch et al. [34]. Briefly, sections were incubated
with a goat polyclonal anti-collagen V IgG antibody
(1350-01 Southern Biotech, Birmingham, AL) 1:100 for
1 h at room temperature. Next, three separate mouse
monoclonal antibodies to detect type 1, slow myosin
IgG 1:100 (MAB1628 Millipore, Burlington, MA), type
2a IgG 1:6 (A4.74 DSHB), and both type 2A and 2X IgG
1:10 (NCL-MHCf Leica Biosystems, Buffalo Grove, IL)
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were conjugated to fluorescent IgG1 Fab fragments using
Zenon® Mouse IgG labeling kits (Life Technologies,
Carlsbad, CA), Alexa Fluor® 488 (A4.74), Alexa Fluor®
594 (NCL-MHCF), and Pacific Blue™ (MAB1628). The
three Zenon® labeled antibodies were mixed together,
added to the tissue sections, and incubated at 4 °C over-
night. A secondary antibody for Collagen V, FITC-rabbit
anti-goat IgG (61-1611, Invitrogen, Carlsbad, CA) 1:500
was applied to the cryosections and incubated for 1 h at
room temperature. Sections were subsequently mounted
using VECTASHIELD mounting medium (H1000,
Vector Labs, Burlingame, CA) and examined using a
fluorescence microscope (Olympus, Tokyo, Japan) with
filters designed for each of the different emitting wave-
lengths. Images were captured and pseudo-colored com-
posites generated.
Statistical methods and data analysis
The total number of type 1, 2A, 2AX, and 2X muscle
fibers was determined for the entire muscle section, and
fiber type compositions were determined by dividing the
total number of fibers of each type by the total number
of muscle fibers counted (range 447 to 3244 muscle
fibers/sample). The fiber type composition of IMM sam-
ples with inflammation and wild-type samples were
compared by genotype and disease status using a two-
way ANOVA.
Results
Pedigree analysis
From the original GWA cohort, pedigrees were available
for 23/36 QH. All affected horses could be traced back to a
common sire within eight generations (Additional file 2:
Figure S1). Pedigree analysis supported either an autosomal
dominant or autosomal recessive mode of inheritance.
Genome-wide association study
Following quality control of the 73,706 SNPs available
on the array, 39,589 SNPs remained (1601 excluded for
minor allele frequency < 1%, 32,439 excluded for geno-
typing < 90%, and 77 excluded for failing hardy Wein-
berg equilibrium [P < 0.001]). Genomic inflation (λ) was
estimated at 1.98, indicative of population stratification.
Due to the elevated genomic inflation, a mixed model
analysis was performed utilizing GEMMA with the same
filters [17]. Using the GEMMA relationship matrix,
genomic inflation was controlled for in the population
(λ = 1.02). Nine SNPs on chromosome 11 reached
genome-wide significance (Table 1 and Fig. 2a).
Haplotype analysis and candidate region
Haplotype analysis of 1109 SNPs on chr11 that passed
quality control (838 removed for genotyping < 90% and
64 removed for minor allele frequency < 1%) using
Table 1 Genome-wide significant single nucleotide (SNP)
polymorphisms for immune-mediated myositis (IMM)
Chr Position Ref Alt p_score
11 54549083 A G 1.52055E−08
11 53982070 C T 4.0689E−08
11 53911268 A G 4.53797E−08
11 53889957 G A 4.78016E−08
11 52379255 A G 1.53355E−07
11 51677777 G A 2.28682E−07
11 54437293 A G 5.70386E−07
11 52382557 T G 8.81654E−07
11 53554776 A G 9.80409E−07
Chr chromosome, Ref reference allele, Alt alternative allele
Fig. 2 a Manhattan plot and (top right insert) QQ-plot demonstrating
a genome-wide significant association with the IMM phenotype using
GEMMA analysis [17] on chr11. Minimal genomic inflation was present.
b Genotypes for the MYH1 E321G variant across IMM-affected horses
(n = 71 GWA and follow-up cohorts combined), at risk horses (n = 75,
housed on the same farms as IMM horses), a cohort of random
QH (n = 28), and 21 other breeds (n = 179)
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Haploview [18] identified 46 significantly associated
haplotype blocks (Ppermuted < 0.05), spanning ~ 6.3 Mb
from chr11: 49,915,548–56,207,873. Of these, four highly
significant haplotype blocks (Ppermuted < 0.001) spanning ~
3.1 Mb from chr11:52379156-55487290 were identified.
This region overlapped the ~ 2.87 Mb region flanked by
eight of the nine genome-wide significant SNPs from the
GWA. Therefore, while the entire 6.3 Mb region was eval-
uated, the 3.1 Mb region was prioritized.
The 6.3 Mb region identified through GWA and subse-
quent haplotype analysis encompassed 148 Ensembl anno-
tated genes, with 277 annotated transcripts in equine
skeletal muscle [35]. Within the 3.1 Mb prioritized region,
38 Ensembl annotated genes and 48 annotated skeletal
muscle transcripts were identified [35]. Of these 38 genes,
four myosin genes (MYH1, MYH2, MYH3, and MYH13)
and myocardin (MYOCD) were located within the associ-
ated region. MYH1 and MYH2 are expressed in adult
equine skeletal muscle while MYH3 is expressed at the
embryonic stage and MYH13 is expressed primarily in
ocular skeletal muscle [36].
Whole-genome sequencing
Whole-genome sequencing was performed on four IMM
and four unaffected QHs at ~ 10× coverage. Visual
inspection of the raw reads using the Integrated Genom-
ics Viewer [26] within the GWA region did not identify
any structural variants across the eight horses. Using
Haplotype Caller according to GATK Best Practices
Recommendations [21, 22], an average of 5,107,127 sin-
gle nucleotide variants (SNVs) and 655,690 insertions/
deletions were identified across all eight horses. Variants
were filtered based on a region of interest from the
GWA and haplotype analysis, spanning the entire
6.3 Mb associated region (chr11:49,915,548–56,207,873),
and 628 variants within this filtered region were signifi-
cantly associated with the IMM phenotype (Fisher’s
exact test, Punadjusted < 0.00003). These 628 variants were
examined in all publically available mapped whole-
genome sequences (n = 110 across 21 breeds) from the
Sequence Read Archive (SRA; https://www.ncbi.nlm.-
nih.gov/sra). Only 15 of these variants were unique to
the QH. As IMM has not been reported in a breed other
than QH-related breeds, the other 613 variants were
excluded from further analysis. The remaining 15 breed-
specific variants were prioritized for further evaluation
(Table 2). Two of these variants were classified as MOD-
ERATE missense variants while other variants were clas-
sified as MODIFIERS (n = 12) or a LOW synonymous
variant (n = 1) (Table 2).
To prioritize these 15 variants for further genotyping,
the custom equine transcriptome recently published by
our laboratory was utilized [35]. These RNA-Seq data-
sets included skeletal muscle and embryo (both inner
cellular mass and trophoectoderm). Within all available
sets, the MYH3 variant was non-coding (Table 2). There-
fore, the MYH1 variant was initially prioritized for geno-
typing of a larger group of horses.
Genotyping of putative variants
DNA from 46/48 horses used in the GWA study was avail-
able for genotyping the MYH1 E321G variant and a
Table 2 Segregating variants for IMM
Variant Ref allele Alternate allele SNPEff Skeletal muscle expression [35] Conservation score
chr11:50,342,189 G A Upstream, ACAP1 Non-coding 0.149
chr11:50,534,985 A AG Intergenic Coding 0
chr11:51,060,046 G A Upstream, TMEM107 Non-coding N/A
chr11:51,248,313 T C Synonymous, KRBA2 Coding 0
chr11:51,282,298 C T Intergenic Non-coding 0
chr11:51,514,034 C T Intergenic Non-coding 0.022
chr11:51,515,343 C T Intergenic Non-coding 1
chr11:51,516,129 C G Intergenic Non-coding 0.006
chr11:51,543,197 T C Intergenic Non-coding 0
chr11:52,944,928 G C Intergenic Non-coding N/A
chr11:52,993,878 T C Missense, MYH1 Coding 1
chr11:53,105,764 C T Missense, MYH3 Non-coding 1
chr11:53,502,949 G GT Intergenic Non-coding 0
chr11:53,795,669 G A Intronic, novel gene
(ENSECAG00000025157)
Non-coding N/A
chr11:53,830,181 C T Intronic, novel gene
(ENSECAG00000025157)
Non-coding N/A
The bold entries are the prioritized region based on significance of haplotype association testing. The italic entries are genotyped in additional cohort
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significant association was identified (P = 6.76 × 10− 15).
Within the follow-up cohort of 35 mildly affected IMM
horses, a significant allelic association was validated
(P = 2.95 × 10− 5) with the MYH1 E321G variant. In
the two IMM cohorts combined, 87.7% of horses
were homozygous or heterozygous for the variant
(Fig. 2b). In the random cohort of QHs without a
history of IMM, three heterozygotes (11%) were iden-
tified. Genotyping of 175 horses across 21 non-QH
breeds did not identify any other breeds with the
MYH1 E321G variant (Fig. 2b).
To further exclude the possibility that additional segregat-
ing variants were responsible for IMM, we genotyped a
subset of horses for chr11:52,944,928 and chr11:53,105,764
in horses that lacked the MYH1 E321G variant but were
classified as IMM based on lymphocytic infiltrates (n = 2 in
GWA and n = 7 in follow-up cohort). The subset of horses
genotyped included the n = 9 IMM-affected horses that
genotyped A/A at chr11:52,993,878, IMM-affected horses
that genotyped G/G (n = 11), and unaffected horses that
genotyped A/A (n = 11). The nine IMM-affected horses
that had genotyped A/A at chr11:52,993,878 also genotyped
for the reference allele at the two other segregating variants,
resembling the unaffected horse genotype. These nine
horses with an inflammatory myopathy therefore appeared
to be phenocopies. In the other IMM-affected horses, the
two other variants are genotyped as alternate allele/alter-
nate allele. Because these variants lacked a strong
functional effect, were non-coding in adult equine skeletal
muscle, and lacked any known connection to immune or
muscle function, the MYH1 E321G variant was identified
as the putative functional variant for equine IMM (Table 2).
Pedigree evaluation based on MYH1 E321G genotype
Available pedigrees were re-evaluated on the 23 IMM-
affected horses based on the MYH1 E321G genotype
and could be distinctly summarized as linking to four
founder stallions (Fig. 3). Two of these founder stallions
were traced back to the stallion in family A within one
to three generations. For family D, the dam line traced
back to the stallion in family A within four generations.
RT-qPCR
There was no significant difference in MYH1 skeletal
muscle expression between IMM-affected horses and
controls (data not shown).
Protein modeling, contact area, and stability analysis
The missense mutation identified in MYH1 is located in
a highly conserved region of the myosin globular head in
subfragment-1 between the helix loop-helix region of
Helix J and Helix K (Fig. 4a, b). The helix loops lay
between SWITCH1 and SWITCH2 motifs that have
been identified as RAS GTP proteins, and play a role in
the binding of ATP [29]. The MYH1 E321G mutation
substitutes a negatively charged glutamic acid (E) for a
Fig. 3 a–d Pedigrees from four subsets of the larger pedigree (Additional file 2: Figure S1) demonstrating a founder effect of four stallions for the
IMM phenotype. Circles = females, squares =males. Open circles = phenotype unknown. Colored circles = IMM-affected with red = G/G genotype,
blue = G/A genotype, and gray = A/A phenotype. Two of these founder stallions were traced back to the stallion in family A within one to three
generations. For family D, the dam line traced back to the stallion in family A within four generations (Additional file 2: Figure S1)
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Fig. 4 (See legend on next page.)
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non-polar glycine (G) that lacks side chains necessary
for hydrogen bond formation. Contact area and solute
accessibility analyses showed that 14 residues were dir-
ectly affected by the MYH1 E321G mutation (Fig. 4c)
with the largest reduction of contact between the
SWITCH1 and helix 1 domains of the myosin 2X globu-
lar head (Fig. 4d, e). Furthermore, this single mutation of
E317G is responsible for significantly decreasing the
stability of the protein at physiological conditions with a
RI score of 8 (Fig. 4f ).
Inflammation and muscle fiber type composition
CD4+ and CD8+ lymphocytes and macrophages were
identified within and surrounding myofibers in all horses
homozygous and heterozygous for the E321G MYH1
variant (Fig. 5a). Inflammatory cells were present in type
2X fibers which contain myosin heavy chain 2X that is
encoded by MYH1 (Fig. 5b, c). Significantly fewer type 2X
fibers (mean 27%; range 0–50%) were found in E321G
MYH1 homozygous and heterozygous samples with
inflammation compared to controls (mean 60; range
43–87%; P < 0.0001) (Fig. 5d, e) Small numbers of inflam-
matory cells, atrophic type 2X fibers, and a predominance
of type 2A and 2AX fibers over 2X fibers were identified
in the semimembranosus muscle of an IMM homozygote
with a 4-month long history of IMM (Fig. 5f–h). In
contrast, in the complete absence of inflammation, the
proportion of type 1, 2A, 2AX, and 2X fibers of control
horses did not differ significantly from IMM muscle
samples (Fig. 5i–k). The mean percentage of type 2X fibers
in IMM E321G horse muscle without inflammatory
infiltrates (4 semimembranosus, 2 gluteal) was 45%,
ranging from 30 to 56%, as compared to control samples
(3 semimembranosus, 2 gluteal), where the mean percent-
age of type 2X fibers was 60%, ranging from 43–87%.
Discussion
This is the first report of a mutation in MYH1 gene
associated with susceptibility to a specific myopathy. A
GWA study initially identified a ~ 6.3 Mb region on
chr11 associated with IMM, and haplotype analyses nar-
rowed this region to ~ 3.1 Mb that encompassed two
myosin genes expressed in adult equine muscle, namely
MYH1, encoding type 2X myosin heavy chain (MyHC),
and MYH2, encoding MyHC 2A. Type 2X fibers com-
prise 40–80% of all fibers and type 2A comprise 30-40%
of all fibers present in muscles typically affected with
IMM [37]. One nonsynonymous variant was identified
in MYH1 that resulted in substitution of a charged
glutamic acid for a non-polar amino acid, glycine, at 321
in the MyHC globular head. Credence for the signifi-
cance of the variant was provided by the fact that
glutamic acid is highly conserved (Table 2), present in
this position in seven other species (Sus, Bos, Homo,
Oryctol, Rat, Canis) and in the corresponding position
of MyHC 2A, perinatal, extraocular, embryonic, and car-
diac/slow MyHC [38]. We propose that the other segre-
gating variants with no known functional effect were in
linkage disequilibrium with this MYH1 functional vari-
ant, although they cannot be conclusively excluded as
putative variants for IMM. The MYH1 E321G variant is
all the more significant, however, because of a strong
selection pressure against mutations in skeletal muscle.
MyHC appears to exist based on the remarkable orthol-
ogy of myosin heavy chain genes across species [38, 39].
Thus, the E321G variant identified in MYH1 in IMM
horses is both novel and strongly associated with suscep-
tibility to develop equine IMM.
The MYH1 E321G variant appears to be variably pene-
trant, conferring susceptibility to disease, potentially
dependent upon whether other factors needed to trigger
an immune-mediated disease are present. A significant
proportion of both IMM and in contact unaffected
horses were heterozygous for the MYH1 E321G variant.
Heterozygosity, however, was much less in the unrelated
group of QH and absent in the Arabian breed of horse
as well as in the publically available mapped NCBI SRA
database of 21 breeds. The high degree of heterozygosity
(See figure on previous page.)
Fig. 4 Schematic representation of MYH1 (MyHC 2X) with wild type (E317E, wt) and MYH1 mutation (E317G, mut). a Wild-type (wt) variant is shown as
light green (red arrow) and E317G mutation (mut) is shown on the adjacent panel as teal (red arrow). In both panels, helices are represented as blue
and additionally loop, SWITCH regions and actin binding sites are labeled. b Detailed alignments of the query protein (upper sequence line) and struc-
ture hits showing the protein sequence (PDB SEQRES record) and the resolved coordinates (PDB ATOM record). The input variant is indicated by green
arrows (below and above the alignment) and highlighted amino acids represent residues that appear in dbSNP as well as common associated somatic
mutation in cancer (COSMIC) variants. c Side chain and stability analysis of MYH1 E317G mutation showing contact surface areas between atoms and
solvent accessible surfaces. Table includes contact surface area (Å2) and minimal atomic distance (Å) between two atoms of the two residues for the 15
amino acid residues that were determined to be impacted by the mutation. d A pictorial presentation of contact/residues affected by the MYH1 E317G
mutation and its association to SWITCH1, helix I and helix J regions of MYH1. The residues affected are represented with an asterisk (*). Helix K is partially
represented. The input variant is indicated by green arrows (below and above the alignment) and highlighted amino acids represent residues that appear
in dbSNP as well as common associated somatic mutation in cancer (COSMIC) variants. e G23D model displaying a close up of combined MYH1 mutation
(teal only) and wild type (green). Blue represent the helices and shows the proximity of the MYH1 mutation to the SWITCH 1 region and to the G677 and
P710 residues found between Loop2 and SH2 helix domain of MYH1. f Stability analysis of the E317G mutation using I-mutant-2 at physiological pH, which
predicts decreased stability of the mutant protein
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in the original cohort of horses can be explained by the
fact that the group of horses in contact with IMM-
affected horses were closely related to the affected
horses. The unadjusted genomic inflation factor for the
initial GWA was 1.98. To control for environmental
exposure to factors such as other respiratory bacteria,
viruses, and vaccinations that can trigger IMM, we
selected horses in the same environment, which was a
breeding farm in one case and a private farm with pref-
erence for certain bloodlines in another [4]. The M pro-
tein of S. equi in particular shows considerable similarity
in amino acid sequence with MyHC 2X (encoded by
MYH1; Additional file 3: Figure S2) and is a common
trigger of IMM [3]. Lack of IMM onset in some hetero-
zygotes could be the result of differential expression of
the affected allele, subthreshold environmental triggering
of autoimmunity, or a lack of initial priming of the
immune system from a first exposure to mutant MyHC
2X. It is also possible that some of the in contact horses
developed IMM at a later stage. Together, our results
suggest that rather than consistently causing a myop-
athy, homozygosity and, in some cases, heterozygosity
for the MYH1 variant predisposed horses to a myopathy
under certain environmental triggers.
Nine of 71 horses diagnosed with IMM and genotyped
for MYH1 E321G were homozygous reference. Of these,
two were from the initial GWA cohort, where horses
were phenotyped more stringently (i.e., moderate to
severe lymphocytic infiltrate on muscle biopsy), and
seven were from the follow-up cohort, where IMM-
affected cases had a milder degree of myofiber lympho-
cytic infiltrates and included those with only perivascular
lymphocytes. As additional nearby variants segregated
with the IMM phenotype at identical frequencies as
Fig. 5 a Marked CD4+ lymphocytic infiltrates (red) within myofibers of horse 1, an E321G MYH1 homozygote. IHC × 20. b Serial section to c demonstrating
inflammatory cell infiltrates (arrows) in horse 1. HE × 20. c Serial section to b demonstrating that fibers infiltrated by lymphocytes (vertical arrows) are 2X fibers
(red) and that some fibers with cellular infiltrates (horizontal arrows) do not have any remaining myosin staining. IF × 20. d Serial section to e from horse 2
showing inflammatory cells (arrows). HE × 10. e Serial section to D demonstrating a complete absence of 2X fibers. Dark regions with no staining (arrows)
correspond to regions of inflammation in D. IF × 10. f Normal fiber type distribution and fiber sizes in another homozygous wild-type horse for comparison.
IF × 20. g Section of muscle from horse 3 that had a 4-month history of IMM showing a small amount of inflammatory cell infiltrates. HE × 10. h Another
section of horse 3 demonstrating atrophic type 2X fibers (brown). IF × 10. i Preponderance of type 2A (yellow) or 2AX fibers (intermediate) over type 2X fibers
(brown) in another region of the sample from horse 3. IF × 10. j Normal fiber type distribution of muscle from a wild-type horse (type 1 blue, type 2A yellow,
type 2X brown) showing type 2X fibers that are larger than type 2A fibers. IF × 10. k Normal fiber type distribution and fiber sizes in the semimembrano-
sus muscle that lacks inflammation from horse 4 that was homozygous for the E321G variant. IF × 20. Bars in all figures represents 100 μm
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MYH1 E321G (Table 2), these nine horses were geno-
typed for these additional variants. All nine horses
genotyped homozygous for the reference allele at the
two additional variants, identical to the population of
unaffected horses. Lymphocytic infiltrates in the skeletal
muscle are not specific for immune-mediated myositis
and can be found in other inflammatory myopathies
[2, 13] with sarcocystosis being the most common
equine infectious myopathy characterized by lympho-
cytic infiltrates [40, 41]. The nine horses lacking the
MYH1 E321G variant could very well represent
phenocopies due to an inflammatory myopathy.
Phenocopies were to be expected because differenti-
ation of immune-mediated versus inflammatory myop-
athies of infectious origin is difficult in horses based
solely on muscle histopathology [2, 13, 42].
In total, 15 variants segregated at identical frequencies
with the IMM phenotype (Table 2). While most of these
variants were classified as having LOW or MODIFIER
effects by SNPEff [23], two were characterized as having
MODERATE effects (missense variants in MYH3 and
MYH1) when using the Ensembl annotation. We have
recently demonstrated that this annotation is not highly
accurate in the horse, and we have published a tissue-
specific transcriptome for the horse based on RNA-
sequencing data and integration with other EquCab2.0
annotations, including NCBI [35]. This custom annota-
tion includes transcriptomes of equine skeletal muscle
and embryo. Across all tissues, the MYH3 variant was
identified as non-coding. Therefore, we propose that
these variants are in linkage disequilibrium with the
MYH1 E321G variant.
Mutations in MYH2 have been reported in a small
number of human patients. Recessive truncating dele-
tions in MYH2 result in early-onset weakness confined
to extraocular, semitendinosus, gracilis, vastus lateralis,
and medial gastrocnemius muscles whereas dominant
point mutations in MYH2 result in a later onset of mild
progressive weakness [43–45]. Both recessive and dom-
inant MYH2 mutations result in mild myopathic changes
such as variability of fiber size, internalized nuclei, and
increased interstitial connective and adipose tissue; how-
ever, only recessive deletions produce a total absence of
type 2A myofibers [43, 45]. Unlike patients with reces-
sive MYH2 mutations, in horses with IMM, the reduc-
tion in type 2X myofibers was dependent upon
inflammation and, in the absence of inflammation,
homozygous IMM horses had a normal proportion of
type 2X fibers. In the small number of samples evaluated
from homozygous horses with chronic atrophy, we
found a decrease in the proportion of type 2X myofibers
with a higher proportion of type 2A and 2AX fibers. Our
results suggest that lymphocytic destruction of MyHC
2X fibers appears to be a prerequisite for acute
inflammation in IMM horses. Previous studies have not
identified immunoglobulin bound to myofibers in IMM
horses [3]; however, circulating anti-MYH1 myosin or
cytokines have not been studied in equine IMM. The
clinical signs and muscle histopathology of IMM appear
to be distinct from those previously reported for MYH2
mutations in other species.
In contrast to the low frequency of mutations in MYH1
and MYH2, more than 500 disease-causing point muta-
tions have been described in MYH7, with the majority
producing hypertrophic or dilated cardiomyopathy [46,
47]. A minority of MYH7 mutations are reported to cause
skeletal myopathies such as myosin storage myopathies or
Laing distal myopathy [46, 47]. One family with a
p.K1729del in MYH7 had similar inflammatory changes to
those seen in equine IMM, although the clinical presenta-
tion was that of distal limb weakness not the rapid prox-
imal muscle atrophy seen in equine IMM [48]. Similar to
equine IMM, increased skeletal muscle MHC class I
expression and perivascular and endomysial lymphocytic
infiltrates (CD3+, CD4+, and CD8+) were found in this
family with Laing distal myopathy, along with rimmed
vacuoles, which are not a feature of equine IMM [6, 48].
Laing distal myopathy has highly variable muscle
pathology, however, and inflammation is not a consistent
feature of the skeletal muscle in most patients [49].
The best characterized link between myosin, inflam-
mation, and muscle disease would be immune-mediated
myocarditis [50]. Fragments of cardiac myosin have been
shown to activate Toll-like receptors (TLR2), which
strongly drive reactivity to self and subsequently deter-
mine the type of adaptive immune response (i.e., Th1,
Th2) that occurs [51]. Synergy between the activated
innate immune response and the adaptive response of
pathogenic T cell epitopes appear to be important in the
generation of chronic myocardial inflammation [51].
Similar to human myocarditis, the adaptive immune
response could be triggered in IMM horses by shared
epitopes between bacteria such as the M protein of
group A Streptococcus sp. and myosin (Additional file 3:
Figure S2) [52]. The innate immune response could be
triggered in IMM by release of the mutant form of
MyHC 2X from myofibers following muscle damage
(trauma, vaccination). The loss of hydrogen bonds with
the MYH1 mutation could possibly lead to conform-
ational changes in myosin that activate TLRs and auto-
immunity. Of note, a nonsynonymous mutations in
MYH7 (S545A) in DBA/2 mice appears to predispose
these mice to immune-mediated myocarditis [53, 54].
When DBA/2 mice with the MYH7 S545A variant and
BALB/c mice without the variant are auto-inoculated
with cardiac myosin, chronic myocarditis only occurs
when serum from the DBA/2 strain is injected into
DBA/2 not BALB/c mice [53]. The authors concluded
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that susceptibility to autoimmune myocarditis was
dependent not only on the activation of self-reactive
lymphocytes but also on genetically determined target
organ sensitivity. Because both the DBA/2 MYH7 muta-
tion and the equine MYH1 variant are located in the
globular head of myosin, it is possible that a mutation in
this highly conserved region somehow confers target
host susceptibility to myositis.
Perhaps the most intriguing link between myosin and
autoimmunity comes from canine masticatory muscle
myositis (CMM). CMM presents with painful swelling
followed by rapid atrophy of masticatory muscles [8].
Similar to equine IMM, biopsies of CMM masseter
muscle are characterized by MHC I upregulation, B cells,
and a predominance of CD4+ over CD8+ T lymphocytic
infiltrates in masticatory muscles [2, 6, 8, 53]. Both within
the masseter muscle and in the circulation, autoantibodies
for masticatory muscle myosin (2M) or myosin binding
protein-C are evident with CMM, suggesting that myosin
isoforms unique to masseter muscles have antigenic po-
tential and can serve as target antigens for inflammatory
cells [55]. Genetic analysis of CMM dogs has yet to be
performed to assess the potential for putative mutations
in masticatory muscle myosin encoding genes to enhance
susceptible to CMM.
Conclusions
In conclusion, an E321G MYH1 mutation is highly associ-
ated with susceptibility to IMM in horses. In the absence
of inflammation, type 2X muscle fiber type composition is
within normal limits in IMM horses; however, within a
particular environment, the MYH1 mutation results in in-
vasion and destruction of type 2X myofibers by lympho-
cytes and rapid onset of gross muscle atrophy.
Additional files
Additional file 1: Table S1. Across breed genotyping. (XLSX 9 kb)
Additional file 2: Figure S1. Within the cohort of genome-wide association
horses affected with IMM, 23/36 had available pedigree information. All affected
horses (red) could be traced back to a common sire within eight generations.
Pedigree analysis supported either an autosomal dominant or autosomal
recessive mode of inheritance. Circles = females, squares =males. (TIFF 7954 kb)
Additional file 3: Figure S2. Protein alignment of MYH1 gene and M
protein of Streptococcus equi (S. equi) (AHI46575.1) showing similarities in
regions of the S. equi alignment and the MYH1 gene. Sequences were
aligned using CLUSTALX (version 2). (TIFF 15425 kb)
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